191543-71-2

Basic information

• Product Name: methyl 3,5-di-O-benzyl-α-D-ribofuranoside
• Synonyms: methyl 3,5-di-O-benzyl-α-D-ribofuranoside
• CAS NO: 191543-71-2
• Molecular Weight: 344.408
• Mol File: 191543-71-2.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: methyl 3,5-di-O-benzyl-α-D-ribofuranoside(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3,5-di-O-benzyl-α-D-ribofuranoside(191543-71-2)
• EPA Substance Registry System: methyl 3,5-di-O-benzyl-α-D-ribofuranoside(191543-71-2)

Safety Data

• Hazardous Substances Data: 191543-71-2(Hazardous Substances Data)

Upstream product

• 64363-77-5 methyl 2,3,5-tri-O-benzyl-β-D-ribofuranoside 
• 67-56-1 methanol 
• 55735-86-9 3,5-O-dibenzyloxy-1,2-O-isorpopylidene-α-D-ribofuranose 
• 13035-61-5 1,2,3,5-tetraacetylribose 
• 10323-20-3 D-Arabinose 
• 37077-81-9 1,2-isopropylidene-α-D-ribofuranose 
• 131139-02-1 (3aS,5R,6R,6aS)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole 
• 114738-04-4 (3aS,5R,6R,6aS)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol 
• 100-44-7 benzyl chloride 
• 168608-39-7 (3S,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydrofuran-2,3,4-triol 
• 532-20-7 D-arabinofuranose 
• 67737-48-8 methyl 5-benzyloxy-β-D-ribofuranoside 
• 100-39-0 benzyl bromide 
• 191543-69-8 1,2-anhydro-3,5-di-O-benzyl-α-D-ribofuranose 

Downstream Products

• 64363-77-5 methyl 2,3,5-tri-O-benzyl-β-D-ribofuranoside 
• 1397371-89-9 4-chloro-7-[2-deoxy-2-fluoro-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 817204-28-7 C₂₀H₂₂O₅ 
• 213313-43-0 methyl 3,5-di-O-benzyl-D-arabinofuranoside 

Relevant articles and documents

Alkylalanes and methyl furanosides: regioselective O-debenzylation or acetal cleavage

Perbenzylated methyl pentofuranosides were submitted to the action of three alkylalanes and regioselective debenzylation at O-2 of the four pentoses was observed when choosing the right match between anomeric configuration and aluminium reagent. Diisobuty

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to halogenated nucleosides optionally conjugated to a phosphorus oxide or pharmaceutically acceptable salts thereof. In certain embodiments, the disclosure relates to conjugate compounds or pharmaceutically acceptable salts thereof comprising an amino acid ester or a sphingolipid or derivative linked by a phosphorus oxide to a nucleotide or nucleoside. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising these compounds for uses in treating infectious diseases, viral infections, and cancer.